NeOnc gets FDA manufacturing feedback for NEO212 tablet transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St set for lower open as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
July 15, 2026 9:00 AM EDTFDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212
CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (NeOnc or the Company), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the chemistry, manufacturing and controls (CMC) development program for NEO212, the Companys novel temozolomide-perillyl alcohol conjugate.
The written feedback was provided in advance of a Type B End-of-Phase... More
